Cardiovascular Systems to Webcast Fiscal 2013 Fourth-Quarter Earnings
Conference Call Wednesday, August 7
Live Webcast at 3:45 p.m. CT (4:45 p.m. ET)
ST. PAUL, Minn. -- July 31, 2013
Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII) will host a live webcast of
its fiscal 2013 fourth-quarter conference call on Wednesday, Aug. 7, 2013, at
3:45 p.m. CT (4:45 p.m. ET). David Martin, president and chief executive
officer, and Larry Betterley, chief financial officer, will discuss the
company’s results for its fiscal fourth quarter ended June 30, 2013, and its
financial outlook. The company will issue a post-market earnings release prior
to the call on Aug. 7.
To access the live webcast, go to the investor section of the company’s
website, www.csi360.com, on the day of the conference call and click on the
webcast icon. A webcast replay will be available beginning at 5:45 p.m. CT the
To participate in the conference call, dial (888) 679-8034 and enter 39331740.
Please dial in at least 10 minutes prior to the call. To pre-register for the
call, log on to the following website:
joining the call, pre-registered participants can enter their PIN code, and
other participants can press *0 to reach the operator, or wait on the line for
If you do not have access to the Internet and want to listen to an audio
replay of the conference call, dial (888) 286-8010 and enter access number
41201456. The audio replay will be available beginning at 5:45 p.m. CT on
Wednesday, Aug. 7, 2013, through 11 p.m. CT on Wednesday, Aug. 14, 2013.
About Cardiovascular Systems, Inc.
Cardiovascular Systems, Inc., based in St. Paul, Minn., is a medical device
company focused on developing and commercializing innovative solutions for
treating vascular and coronary disease. The company’s Orbital Atherectomy
Systems treat calcified and fibrotic plaque in arterial vessels throughout the
leg in a few minutes of treatment time, and address many of the limitations
associated with existing surgical, catheter and pharmacological treatment
alternatives. The U.S. FDA granted 510(k) clearance for the use of the
Diamondback Orbital Atherectomy System in August 2007. To date, nearly 110,000
of CSI’s devices have been sold to leading institutions across the United
States. CSI has also completed its ORBIT II Investigational Device Exemption
clinical trial to evaluate the safety and effectiveness of its orbital
technology in treating coronary arteries. The coronary system is limited by
federal law to investigational use and is currently not commercially available
in the United States.
For more information, visit the company’s website at www.csi360.com.
Cardiovascular Systems, Inc.
Investor Relations, 651-259-2800
Padilla Speer Beardsley Inc.
Marian Briggs, 612-455-1742
Matt Sullivan, 612-455-1709
Press spacebar to pause and continue. Press esc to stop.